Stock Track | Halozyme Therapeutics Soars 6.91% in Pre-Market on Q1 Earnings Beat

Stock Track05-12

Halozyme Therapeutics' stock surged 6.91% in pre-market trading on Tuesday.

The sharp rise comes after the biotechnology company reported better-than-expected first-quarter results. Halozyme posted adjusted earnings per share of $1.6, surpassing the IBES estimate of $1.53.

The positive earnings surprise triggered buying interest, extending gains from the post-market session where the stock was already trading higher following the results announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment